These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24637775)
1. Identification of peptide sequences as a measure of Anthrax vaccine stability during storage. Whiting G; Wheeler JX; Rijpkema S Hum Vaccin Immunother; 2014; 10(6):1669-81. PubMed ID: 24637775 [TBL] [Abstract][Full Text] [Related]
2. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Whiting GC; Rijpkema S; Adams T; Corbel MJ Vaccine; 2004 Oct; 22(31-32):4245-51. PubMed ID: 15474715 [TBL] [Abstract][Full Text] [Related]
3. Characterization of the UK anthrax vaccine and human immunogenicity. Modi T; Gervais D; Smith S; Miller J; Subramaniam S; Thalassinos K; Shepherd A Hum Vaccin Immunother; 2021 Mar; 17(3):747-758. PubMed ID: 32897798 [TBL] [Abstract][Full Text] [Related]
4. Development of a novel multiepitope chimeric vaccine against anthrax. Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633 [TBL] [Abstract][Full Text] [Related]
6. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes. Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664 [TBL] [Abstract][Full Text] [Related]
7. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses. Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469 [No Abstract] [Full Text] [Related]
8. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model. Varshney A; Kumar M; Nagar DP; Pal V; Goel AK Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791 [TBL] [Abstract][Full Text] [Related]
9. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Baillie LW; Huwar TB; Moore S; Mellado-Sanchez G; Rodriguez L; Neeson BN; Flick-Smith HC; Jenner DC; Atkins HS; Ingram RJ; Altmann DM; Nataro JP; Pasetti MF Vaccine; 2010 Sep; 28(41):6740-8. PubMed ID: 20691267 [TBL] [Abstract][Full Text] [Related]
10. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913 [TBL] [Abstract][Full Text] [Related]
11. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191 [TBL] [Abstract][Full Text] [Related]
12. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Welkos S; Little S; Friedlander A; Fritz D; Fellows P Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699 [TBL] [Abstract][Full Text] [Related]
13. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model. Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336 [TBL] [Abstract][Full Text] [Related]
14. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734 [TBL] [Abstract][Full Text] [Related]
15. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits. Lee DY; Chun JH; Ha HJ; Park J; Kim BS; Oh HB; Rhie GE FEMS Immunol Med Microbiol; 2009 Nov; 57(2):165-72. PubMed ID: 19732139 [TBL] [Abstract][Full Text] [Related]
16. Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R. Zai X; Zhang J; Liu J; Liu J; Li L; Yin Y; Fu L; Xu J; Chen W Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26927174 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the human immune response to the UK anthrax vaccine. Baillie L; Townend T; Walker N; Eriksson U; Williamson D FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Taft SC; Weiss AA Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590 [TBL] [Abstract][Full Text] [Related]
19. Characterisation of the immune response to the UK human anthrax vaccine. Baillie L; Hebdon R; Flick-Smith H; Williamson D FEMS Immunol Med Microbiol; 2003 May; 36(1-2):83-6. PubMed ID: 12727370 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]